Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Uterocervical Cancer Vaccination Cuts Medical Spending by \43 Billion
August 25, 2008
- Risk Assessment Shows Acceptability of Raw Materials for Basiliximab, Alteplase
August 25, 2008
- Over 40% of Patients Could Stop Remicade for Over 1 Year
August 25, 2008
- EAD to Prepare Industry-Friendly Environment: New Director Kinoshita
August 25, 2008
- JODA Introduces Voluntary GL on Sale of OTC Drugs Online
August 25, 2008
- Mr Masuzoe Reappointed Health Minister
August 25, 2008
- Seven & i, Ain to Tie Up in Operating Dispensing Pharmacies
August 25, 2008
- COMMENTARY／1st Qtr Business Wrap-up for Top-Four Domestic Pharmas
August 25, 2008
- BUSINESS NEWS IN BRIEF
August 25, 2008
- Wholesalers' SGA Expense Ratio Drops to below 7% for the First Time
August 25, 2008
- Eliminating Losses due to Invoice Prices Higher than Sales Prices Is Not Easy: Mr Matsutani
August 25, 2008
- SSP Aims at Growth Rate 2 Points Above Industry Average: President Hatori
August 25, 2008
- Price Settlement Rate Reaches 53% as of July 31: Mediceo Paltac
August 25, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 25, 2008
- Price Settlement Rates as of End of June Similar to Those Reported 2 Years Ago
August 25, 2008
- Survival Improved by Treatment of Post-stroke Depression
August 11, 2008
- Taxotere to Be Approved for Prostate Cancer
August 11, 2008
- Vaccines Effective in Preventing Bacterial Meningitis: Wyeth
August 11, 2008
- GSK's Lamotrigine Recommended for Approval
August 11, 2008
- Long-term Lipovas Administration Useful: Banyu
August 11, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…